主要组织相容性复合体I类递呈途径抗原肽来源的研究进展  

Advances in the research of antigenic peptide sources of major histocompatibility class-I presentation pathway

作　　者：邱思煌 赵长久[1] 

机构地区：[1]哈尔滨医科大学附属第四医院核医学科,150001

出　　处：《国际免疫学杂志》2017年第3期336-340,共5页International Journal of Immunology

摘　　要：近年来,主要组织相容性复合体（MHC）-Ⅰ类递呈途径抗原肽的来源备受争议.选择性翻译产物作为抗原肽来源的模式,对经典全长蛋白降解作为抗原肽来源的模式提出了挑战,且这一模式已经被科学地实验数据证实和支持.因此,现在需要新的假说来探寻不同来源的抗原肽对MHC-I类递呈途径的生理意义.The source of peptides in the major histocompatibility class-Ⅰ （MHC-Ⅰ） pathway has been intensively debated in recent years.The initial assumption that peptides are derived from the degradation of full length proteins was challenged by a model in which alternative translation products are a source of peptides.This model has been supported and tested by scientific data.Now need new assumption on the physiological implications of different sources of peptides for the MHC-Ⅰ pathway.The aim of this review is to give an up-to-date account of the source of antigenic peptide material for the MHC-Ⅰ pathway and to incorporate the more recent observations of alternative mRNA translation products into existing models of the direct and cross-presentation pathways.

关 键 词：抗原肽 主要组织相容复合体-Ⅰ 选择性翻译产物 直接递呈途径 交叉递呈途径 

分 类 号：R392[医药卫生—免疫学]